Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.61 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.61 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.61 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.59 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | SIRT1 | Q96EB6 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29712456 | 1.00 | HDAC8 (0.61) | HDAC8HDAC6HDAC1HDAC2KCNK3 | |
| SCHEMBL18397777 | 0.84 | HDAC8 (0.61) | HDAC8HDAC6HDAC1HDAC2KCNK3 | |
| SCHEMBL6846433 | 0.84 | FOLH1 (0.62) | HDAC8HDAC6HDAC1HDAC2KCNK3 | |
| SCHEMBL12228481 | 0.84 | HDAC1 (0.61) | HDAC8HDAC6HDAC1HDAC2KCNK3 | |
| SCHEMBL19964495 | 0.84 | LOXL2 (0.62) | HDAC8HDAC6HDAC1HDAC2KCNK3 | |
| SCHEMBL30802680 | 0.83 | KCNK3 (0.68) | KCNK3KCNK9KDM4EKMT2ANPC1 | |
| SCHEMBL29200419 | 0.83 | KCNK3 (0.68) | KCNK3KCNK9KDM4EKMT2ANPC1 | |
| SCHEMBL2896309 | 0.83 | RAB9A (0.65) | KMT2ANPC1RAB9ASMN1; SMN2MEN1 | |
| Hydrochloric Acid SCHEMBL19953267 | 0.83 | LOXL2 (0.62) | HDAC8HDAC6HDAC1HDAC2KCNK3 | |
| SCHEMBL29994466 | 0.83 | HDAC8 (0.59) | HDAC8HDAC6HDAC1HDAC2KCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002397-A1 | SMALL MOLECULE DEGRADERS OF HELIOS AND METODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| US-20230002397-A1 | SMALL MOLECULE DEGRADERS OF HELIOS AND METODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-01-05 | — | — | US | disclosed |
| EP-4051386-A1 | SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | Dana-Farber Cancer Institute, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| CN-114650868-A | Small molecule degradation agent of HELIOS and use method thereof | 达纳-法伯癌症研究公司 | 2022-06-21 | — | — | CN | disclosed |
| WO-2021087093-A1 | SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-06 | — | — | WO | disclosed |
| EP-1317443-B1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC (CA) | 2009-01-14 | — | — | EP | disclosed |
| US-20080090846-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | GENZYME CORPORATION | 2008-04-17 | — | — | US | disclosed |
| US-20080090846-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | GENZYME CORPORATION | 2008-04-17 | — | — | US | disclosed |
| US-20080090846-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | GENZYME CORPORATION | 2008-04-17 | — | — | US | disclosed |
| US-7312234-B2 | Chemokine receptor binding heterocyclic compounds | ANORMED (CA) | 2007-12-25 | — | — | US | disclosed |
| US-6835731-B2 | Viricides; antiinflammatory agents; antiallergens; antiarthritic agents | ANORMED, INC. (CA) | 2004-12-28 | — | — | US | disclosed |
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BENDER STEVEN LEE (US) | 2004-05-13 | — | — | US | disclosed |
| CN-1458929-A | Chemokine receptor binding heterocyclic compounds | ANORMED INC (CA) | 2003-11-26 | — | — | CN | disclosed |
| US-6635641-B2 | For treating cancer and other disease states associated with unwanted angiogenesis and/or cellular proliferation such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis, psoriasis | AGOURON PHARMACEUTICALS, INC. | 2003-10-21 | — | — | US | disclosed |
| EP-1317443-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2003-06-11 | — | — | EP | disclosed |
| EP-1252146-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2002-10-30 | — | — | EP | disclosed |
| US-20020147192-A1 | Chemokine receptor binding heterocyclic compounds | GENZYME CORPORATION | 2002-10-10 | — | — | US | disclosed |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, INC. | 2002-08-01 | — | — | US | disclosed |
| WO-2002022599-A2 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | ANORMED INC. (CA) | 2002-03-21 | — | — | WO | disclosed |
| WO-2001053274-A1 | AMIDE COMPOUNDS FOR INHIBITING PROTEIN KINASES | AGOURON PHARMACEUTICALS, INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230002397-A1 | SMALL MOLECULE DEGRADERS OF HELIOS AND METODS OF USE | IKZF2, IKZF1, HELZ | HDAC8 282/4885HDAC6 333/4885HDAC1 561/4885 |
| US-20020147192-A1 | Chemokine receptor binding heterocyclic compounds | CCR2, CXCR3, ACKR3 | HDAC8 1707/4885HDAC6 1162/4885HDAC1 1482/4885 |
| US-20040092747-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | HDAC8 1160/4885HDAC6 960/4885HDAC1 828/4885 |
| US-20020103203-A1 | Amide compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | BRAF, CNKSR1, UACA | HDAC8 1160/4885HDAC6 960/4885HDAC1 828/4885 |
| US-20080090846-A1 | CHEMOKINE RECEPTOR BINDING HETEROCYCLIC COMPOUNDS | CCR2, CXCR3, ACKR3 | HDAC8 1707/4885HDAC6 1162/4885HDAC1 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.